Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Retained Earnings (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Retained Earnings readings, the most recent being -$197000.0 for Q4 2023.

  • On a quarterly basis, Retained Earnings rose 99.82% to -$197000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was -$197000.0, a 99.82% increase, with the full-year FY2023 number at -$197000.0, up 99.82% from a year prior.
  • Retained Earnings hit -$197000.0 in Q4 2023 for Elicio Therapeutics, up from -$133.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $302000.0 in Q3 2022 to a low of -$258.5 million in Q1 2023.
  • Median Retained Earnings over the past 4 years was -$133.3 million (2023), compared with a mean of -$133.2 million.
  • The widest YoY moves for Retained Earnings: up 100.13% in 2022, down 103791.26% in 2022.
  • Elicio Therapeutics' Retained Earnings stood at -$333000.0 in 2020, then soared by 69.07% to -$103000.0 in 2021, then plummeted by 103791.26% to -$107.0 million in 2022, then skyrocketed by 99.82% to -$197000.0 in 2023.
  • The last three reported values for Retained Earnings were -$197000.0 (Q4 2023), -$133.3 million (Q3 2023), and -$122.6 million (Q2 2023) per Business Quant data.